Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    26-November-2000      
Issue 227 Next Update - 14:00 UTC 08:00 EST    27-November-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Angiogenesis Inhibitors In Clinical Trials

Overview Of Some Of The Current Trials Of Anti-Angiogenesis Agents

This page will be updated on a regular basis, and is intended as an overview of some of the current trials of anti-angiogenesis agents. It is not a comprehensive summary of all of the clinical trials ongoing with drugs that inhibit angiogenesis. Therefore, there may be additional trials, and additional sponsors, not represented here. More information can be obtained from the NCI clinical trials database online, where all these studies are listed, or by calling 1-800-4-CANCER regarding trials sponsored by the National Cancer Institute or trials sponsored by drug companies that are voluntarily listed in the database. For information regarding drugs and trials not listed here, you will need to contact the drug company sponsor directly.

The National Cancer Institute (NCI) invites trial sponsors and investigators to submit their trials to the NCI database. If you or your company are interested in participating, see Questions and Answers about Submitting Trials to PDQ for further information and links to an electronic submission form and checklist, that is supported by the NCI. This information is separate from Vidyya and is a link to an outside source.

Drugs that block matrix breakdown:
Drug Sponsor Trial Mechanism For More Info:
Marimastat British Biotech; Annapolis, MD Phase III non-small cell lung, small cell lung, breast cancers. Synthetic inhibitor of matrix metalloproteinases (MMPs) 800-355-6957

or

800-4-CANCER

Online Information

AG3340 Agouron; LaJolla, CA Phase II glioblastoma multiforme. Synthetic MMP inhibitor 888-849-6482

or

800-4-CANCER

Online Information

COL-3 Collagenex; Newtown, PA Phase I/II brain. Synthetic MMP inihibitor. Tetracycline® derivative 800-4-CANCER

Online Information

Neovastat Aeterna; Québec Phase III renal cell (kidney) cancer, Phase III non-small cell lung cancer. Naturally occurring MMP inhibitor 888-349-3232

Online Information

BMS-275291 Bristol-Myers Squibb; Wallingford, CT Phase II/III Advanced or Metastatic Non-Small Cell Lung. Synthetic MMP inhibitor 203-677-6779

Online Information



Drugs that inhibit endothelial cells directly:
Drug Sponsor Trial Mechanism For More Info:
Thalidomide Commercially available, approved for leprosy; Celgene Phase I/II for advanced Melanoma, Phase II head and neck cancer, ovarian, metastatic prostate, and Kaposi's sarcoma; Phase II with chemotherapy against solid tumors; adjuvant study in recurrent or metastatic colorectal cancer; Phase II Graft vs Host Disease; Phase II gynecologic sarcomas, liver cancer; multiple myeloma; CLL, Recurrent or Progressive Brain, Phase III non-small cell lung, nonmetastatic prostate, refractory multiple myeloma, renal cancer. Unknown 732-805-3905

or

800-890-4619 ext. 3905

or

800-4-CANCER



Online Information

Squalamine Magainin Pharmaceuticals; Plymouth Meeting, PA Phase II non small cell lung cancer; Phase II Ovarian; Phase I Advanced Cancers. Extract from dogfish shark liver; inhibits sodium-hydrogen exchanger, NHE3 610-941-4020

or 800-4-CANCER

Online Information (Link to Magainin Web site)

Endostatin EntreMed; Rockville, MD Phase I solid tumor studies. Inhibition of endothelial cells University of Wisconsin
800-622-8922

M.D. Anderson Cancer Center
800-392-1611

Dana-Farber Cancer Institute
617-632-5100

Online Information



Drugs that block activators of angiogenesis:
Drug Sponsor Trial Mechanism For More Info:
SU5416 Sugen; South San Francisco, CA Phase I recurrent head & neck, advanced solid tumors, stage IIIB or IV breast cancer; Phase I advanced malignancies, recurrent or progressive brain(pediatric); Ovarian, Phase I with chemotherapy against solid tumors; Phase I/II AML; Phase I/II glioma, advanced malignancies, advanced colorectal, Phase II von-Hippel Lindau disease, advanced soft tissue; Phase II prostate cancer, colorectal cancer, metastatic melanoma, multiple myeloma, malignant mesothelioma: metastatic renal, advanced or recurrent head and neck, Phase III metastatic colorectal cancer. Blocks VEGF receptor signaling 800-SUGEN-06

or

650-553-8678

or

800-4-CANCER

Online Information

SU6668 Sugen; South San Francisco, CA Phase I against advanced tumors. Blocks VEGF, FGF, and PDGF receptor signaling 800-SUGEN-06

or

650-553-8678

Online Information (Link to Sugen Web site)

Interferon-alpha Commercially available Phase II/III (search* NCI trials database for listings). Inhibition of bFGF and VEGF production 800-4-CANCER
Anti-VEGF Antibody National Cancer Institute, Bethesda, MD; Genentech, San Francisco, CA Phase I refractory solid tumors. Phase II metastatic renal cell cancer. Monoclonal antibody to vascular endothelial growth factor (VEGF) 888-624-1937

or

800-4-CANCER

Online Information


*When searching for interferon-alpha trials in the NCI database, select "cytokine therapy," rather than "antiangiogenesis therapy," in the modality field.

Drugs that inhibit endothelial-specific integrin/survival signaling:
Drug Sponsor Trial Mechanism For More Info:
EMD121974 Merck KCgaA; Darmstadt, Germany Phase I in patients with advanced or metastatic cancer, Phase I in patients with HIV related Kaposi's Sarcoma, Phase I/II progressive or recurrent Anaplastic Glioma Small molecule blocker of integrin present on endothelial cell surface

800-4-CANCER


Online Information



Drugs with non-specific mechanism of action:
Drug Sponsor Trial Mechanism For More Info Call:
CAI National Cancer Institute, Bethesda, MD Phase I studies in combination against solid tumors; Phase II ovarian cancer; advanced renal cell cancer, metastatic renal cell cancer, Phase III non-small cell lung cancer. Inhibitor of calcium influx 800-4-CANCER

or

888-624-1937

Online Information

Interleukin-12 Genetics Institute; Cambridge, MA Phase I/II Kaposi's sarcoma; Phase I/II Interleukin-12 gene therapy. Up-regulation of interferon gamma and IP-10 800-4-CANCER


Online Information

IM862 Cytran; Kirkland, WA Phase I recurrent ovarian cancer; Phase II for untreated metastatic cancers of the colon and rectal; Phase III Kaposi's sarcoma. Unknown mechanism 425-889-5808

or

800-4-CANCER

Online Information


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.